Phase 1 Mesothelioma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are generally healthy and able to carry out daily activities with little to no limitation (this is measured by a standard scale called ECOG, scored 0 or 1)
- Your cancer can be measured or evaluated using standard imaging guidelines
- Your organs (such as liver, kidneys, and bone marrow) are functioning well enough to participate
- You have an advanced cancer that is associated with a protein called mesothelin (confirm with trial site which cancer types qualify)
Who may not be able to join:
- You have a serious active infection that is not under control, or another medical condition that the trial doctor believes would make it unsafe for you to participate
- You have previously received a treatment that targeted mesothelin using a specific type of immune therapy (known as CD3 or CAR-T therapy)
- You are currently taking part in another clinical research trial
- There is evidence that your cancer has spread to the membranes surrounding your brain or spinal cord
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Karen Chagin, MD, Context Therapeutics Inc.
Phone: 267-225-7416
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the MTD or RD of CT-95 [Safety and Tolerability]; Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.